Previously, we have demonstrated that NRF2 plays a key role in mediating cisplatin resistance in ovarian cancer. To further explore the mechanism underlying NRF2-dependent cisplatin resistance, we stably overexpressed or knocked down NRF2 in parental and cisplatin-resistant human ovarian cancer cells, respectively. These two pairs of stable cell lines were then subjected to microarray analysis, where we identified 18 putative NRF2 target genes. Among these genes, ABCF2, a cytosolic member of the ABC superfamily of transporters, has previously been reported to contribute to chemoresistance in clear cell ovarian cancer. A detailed analysis on ABCF2 revealed a functional antioxidant response element (ARE) in its promoter region, establishing ABCF2 as an NRF2 target gene. Next, we investigated the contribution of ABCF2 in NRF2-mediated cisplatin resistance using our stable ovarian cancer cell lines. The NRF2-overexpressing cell line, containing high levels of ABCF2, was more resistant to cisplatininduced apoptosis compared to its control cell line; whereas the NRF2 knockdown cell line with low levels of ABCF2, was more sensitive to cisplatin treatment than its control cell line.
Ovarian cancer is the most lethal type of gynecological cancer with a 5-yr survival rate less than 25%. 1, 2 Cytoreductive surgery plus platinumbased chemotherapy is the first line of treatment, but due to chemoresistance, this therapy has limited efficacy. 3 Nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) overexpression has been reported to correlate with chemoresistance in a variety of cancer types. [4] [5] [6] Our previous study has shown that high levels of NRF2 also correlate with cisplatin resistance in ovarian cancer cells. 7 However, the major NRF2 target genes contributing to NRF2-dependent cisplatin resistance in ovarian cancer are still not fully characterized.
The ATP-binding cassette (ABC) transporters are a superfamily of proteins that utilize ATP as an energy source to transport various molecules across membranes. 8 The majority of ABC members, has nucleotide-binding domains (NBD) and transmembrane domains (TMD), and function as energy-dependent transporters that efflux cytotoxic drugs out of the cell. The increased efflux activity mediated by ABC transporters has an important impact on pharmacological treatments including chemotherapy. 9 Several ABC transporters have been reported to induce chemoresistance, including: P-glycoprotein (ABCB1), multidrug resistance protein 1-6 (MRP1-6/ABCC1-6), and breast cancer resistance protein (BCRP/ABCG2). 10 More importantly, functional antioxidant response elements (AREs) have been identified in the promoter region of a subset of ABC transporters including MRP2, MRP3, MRP4, and ABCG2, which helps define them as NRF2
target genes. [11] [12] [13] [14] It is conceivable that these NRF2-target genes contribute to observed chemoresistance through rapid elimination of chemotherapeutic drugs in the cancer types that have high levels of NRF2. [15] [16] [17] A subgroup of the ABC transporter superfamily is the ABCF transporters, which contains three members, ABCF1, ABCF2, and ABCF3. 18, 19 Unlike other subgroups, ABCF members have NBDs but not TMDs, and thus do not function as transporters of molecules across the membrane. Instead, they are reported to be involved in protein translation and elongation. 18, 20 Of the three ABCF subgroup members, ABCF2 is expressed at significantly higher levels in clear cell ovarian cancer than other types, and therefore it may function as a prognostic indicator for clear cell ovarian cancer. [21] [22] [23] In addition, ABCF2 gene amplification was identified in cisplatin-resistant cancer cell lines, indicating a possible role of ABCF2 in modulating cisplatin resistance. 24 However, current studies are limited to correlating ABCF2 expression with clinicopathological features in different tumor tissues, which does not provide direct evidence that ABCF2 contributes significantly to cisplatin resistance. Furthermore, the molecular mechanism by which ABCF2 is overexpressed in clear cell ovarian cancer cells remains unknown.
In this study, we provide strong evidence that ABCF2 is an NRF2 target gene that contains a functional ARE sequence in the promoter.
We have also demonstrated that modulation of ABCF2 levels can alter the sensitivity of ovarian cancer cells to cisplatin. Therefore, our study suggests that targeting ABCF2 could be a promising therapeutic strategy to re-sensitize ovarian cancer cell lines with high levels of NRF2 to cisplatin treatment. and A2780cp), pLenR-GPH vector alone or containing human shNRF2 was generated and transduced using the same method describe above. Successfully transduced cells were selected using 3 µg/mL puromycin.
| Cell viability and apoptosis
Cell viability was measured using the Cell Counting Kit-8 (Dojin Laboratory, Kumamoto, Japan). Apoptotic cells were detected using either the Annexin V-FITC staining kit (BD Pharmingen, CA) in combination with flow cytometry, or the TUNEL in situ cell death detection kit (TMR red, Roche, IN). 7 For the TUNEL assay, cell images were randomly captured in 10 different fields for each group. Then all of the cells were counted. The percentage of cells with red staining was determined and represented as an apoptosis ratio.
| Immunoblot and immunofluorescence (IF)
Immunoblot and Immunofluorescence analyses were performed as previously described. 25 Antibodies specific for NRF2 (1:1000 for WB, Quantitative real-time PCR was performed as previously described. 7 The primers used for the measurement of ABCF2 and β-actin levels were as follows: hABCF2, forward, GGAGCTGGATGCCGACAA, reverse, CTGCATGGCAGGTGTGAAAC; hβ-actin, forward, CCTCGCCTTTG CCGATCC, reverse, CGTGCTCGATGGGGTACTTC. Two independent experiments, each with duplicate samples, were performed.
| Microarray analysis
For DNA microarray analyses, 1 × 10 7 A2780, A2780-NRF2, A2780cp, and A2780cp-NRF2-shRNA cells were harvested, and total RNA was extracted and reverse transcribed to cDNA. Then the cDNA was sent out to Kangchen company (Shanghai, China) and analyzed in a whole human genome microarray chip for further analysis (Agilent, CA). Each sample was performed in triplicate. The obtained data were analyzed using Gene Ontology for enrichment analysis.
| ABCF2 cloning
One putative ARE was identified in the promoter of ABCF2 using the pDRAW32 1.1.130 software to search for the core ARE sequence (RTGABNNNGCR). 13 A portion of the human ABCF2 promoter (−1292 bp to +1069 bp) containing the putative ARE sequence (GTGACTTTGCA) was then amplified by PCR using human genomic DNA as a template and the following primers: forward, GACAGGGTC-TAGTTTTGTCAC; reverse, CTGTGGTCTCTCTGCCATTGGC. The amplified fragments were then digested with the BglII and HindIII restriction enzymes, and cloned into the pGL4.22 vector (Promega, WI). Another construct where the region containing the ARE (−893 bp to +1069 bp) was deleted was also amplified from the full-length promoter above using the following primers: forward, GGAGCAA-TAGCTTCCTTTGCTG; reverse, CTGTGGTCTCTCTGCCATTGGC. Using the wild-type promoter of ABCF2 as the template, the oligo CTCCCTGAGGTCAGGGAGgGcCTTTGCACCATTGCAACTCCAGC was used to perform site-directed mutagenesis of the ARE (GgGcCTTTGCA).
To generate an ABCF2 expression plasmid, the first region of ABCF2 cDNA was PCR amplified with the following primers: forward, ATGCCCTCCGACCTGGCCAAGAAGA, and reverse, GCTTGGACTT-GAGGTGCT. The isolated product was then digested using the restriction enzymes EcoR1 and Not1, and the DNA fragment was cloned into the pCMV-HA vector (Promega). The second region of the ABCF2 cDNA was amplified using the following primers: forward, GGACTTAGATCTCTCACCTTTG; reverse, TCATGGCCTTGGCAGA-GATGC. The amplified fragment was again digested using BglII and Not1 and ligated into the plasmid containing the first region of ABCF2
cDNA. Correct cloning of the gene was verified by sequencing.
| Dual luciferase assay
The dual luciferase assay was performed according to the manufac- 
| Small interfering RNA transfection
Human NRF2 siRNA (SI00659737) and nonspecific control siRNA (102728) were purchased from Qiagen (MD). Human ABCF2 specific siRNAs were obtained from RiboBio (Guangzhou, China). The #1, #2
and #3 ABCF2 siRNA sequences were as follows: #1) CCTCTCACT-TACCTTTCAT, #2) GGTCGTGAGCGATAAGACA and #3) TGAGCTT-CAAGTATACAAA. Human KEAP1 specific siRNA were targeting GGCCUUUGGCAUCAUGAACTT (RiboBio). Hiperfect reagent (Qiagen) was used for siRNA transfections according to the manufacturer's protocol.
| Chromatin immunoprecipitation assay (CHIP)
CHIP assay was performed according to the manufacturer's instruc- | 1545 formaldehyde in the medium, then incubated at room temperature for 10 min. All cells were washed with cold PBS with protease inhibitor cocktail (Roche) and were suspended in 1 mL SDS lysis buffer containing protease inhibitor cocktail. All samples were sonicated for 27 min and were centrifuged at 15 000g for 10 min at 4°C.
Solubilized chromatin (100 µL) was diluted with CHIP dilution buffer (900 µL) for CHIP assays. And 100 µL diluted solubilized chromatin was saved for total chromatin input. Chromatin was precleared with protein G-agarose for 60 min at 4°C and then incubated with NRF2
antibody (ab62352, Abcam), or rabbit IgG overnight at 4°C with rotation. Cross-linked immunoprecipitates and total chromatin input were reverse crosslinked and DNA was extracted and purified. Then, 1 µL of DNA was used for PCR with primers specific for the ABCF2
promoter. For PCR amplification, forward primer: 5′-AAAT-GATCCTCCCACTACGG-3′ and reverse primer: 5′-GAATATCCTC-CACCAACGAA-3′ from Gebewiz (Shanghai, China) were used.
| Statistical analysis
Data are presented as the mean ± SD. Student's t-test or one way analysis of variance (ANOVA) was used to assess the significance among groups using the SPSS 16.0 software. P < 0.05 was considered to be a significant difference.
3 | RESULTS 3.1 | NRF2 levels are highly expressed in HGSOC tissue and cisplatin resistant A2780 ovarian cancer cell lines
First, immunohistochemical analysis of human tissues from nine individual patients revealed that the HGSOC tissues had significantly higher levels of NRF2 compared to their NOT controls (Fig. 1A) . The NRF2 IHC score of the cancer tissues is significantly higher than the normal tissues from the same patient (P < 0.01, These results indicate that high expression of NRF2 correlates with chemoresistance in ovarian cancer.
| NRF2 expression regulates cisplatin sensitivity in ovarian cancer cells
To test the role of NRF2 expression in regulating cisplatin resistance, we stably overexpressed or knocked down NRF2 in the parental (A2780) and cisplatin-resistant (A2780cp) human ovarian cancer cells, respectively. The two pairs of cell lines generated were A2780 (vector control) and A2780-NRF2 (NRF2 overexpression), as well as A2780cp
(vector control) and A2780cp-NRF2-shRNA (NRF2 knockdown). The protein levels of NRF2 and its downstream gene NQO1 were measured using immunoblot analysis to confirm NRF2 overexpression or knockdown ( Fig. 2A and B) . Sensitivity of these cell lines to cisplatin treatment was compared using a cell viability assay. Cisplatin treatment decreased cell viability in a dose-dependent manner in all four lines, with A2780-NRF2 cells being more resistant to cisplatin than the A2780 vector control cells, and A2780cp-NRF2-shRNA cells being more susceptible to cisplatin toxicity than A2780cp vector control cells (Fig. 2C and D) . The cell viability data revealed that the half maximal effective concentration (EC50) of cisplatin at 48 h in A2780-NRF2 and A2780 was 1.97 ± 0.11 µg/mL and 0.64 ± 0.16 µg/mL, respectively (P < 0.05, Fig. 2C) ; whereas the EC50 of cisplatin in A2780cp-NRF2-shRNA and A2780cp cells was 9.34 ± 0.53 µg/mL and 13.64 ± 0.23 µg/mL, respectively (P < 0.05, Fig. 2D ). TUNEL staining of cells treated with cisplatin for 24 h revealed that the number of apoptotic cells in the A2780-NRF2 cell line was 2.19 ± 0.64% compared to 7.07 ± 2.75% in the A2780 vector control cell line (P < 0.01, Fig. 2E ), and the number of apoptotic cells in the (E and F) Analysis of apoptosis. A2780-NRF2 and A2780 cells were treated with 1 µg/mL cisplatin (E) and A2780cp-NRF2-shRNA and A2780cp cells were treated with 10 µg/mL cisplatin (F) for 24 h to determine apoptosis by TUNEL assay. All data are presented as mean ± SD from three independent experiments, n = 3. *P < 0.05, **P < 0.01
A2780cp-NRF2-shRNA cell line was 38.81 ± 33.84% compared to 3.4 ± 0.38% in the A2780cp vector control cell line (P < 0.01, Fig. 2F ).
These data suggest that NRF2 effectively regulates the sensitivity of ovarian cancer cells to cisplatin.
| Identification of putative NRF2 target genes by DNA microarray analysis
For microarray analysis, only genes with a ∼1.5-fold change in each pair of cell lines were included in the enrichment analysis. Results showed that 859 genes were upregulated in A2780-NRF2 compared to A2780
vector control cells, whereas 396 genes were downregulated in A2780cp-NRF2-shRNA compared to A2780cp vector control cells (Fig. 3A) . Among the genes that changed, 18 genes were identified to be potentially regulated by NRF2, including IL18, TRMT61A, ABCF2, HGD, NEFH, LEO1, PRR22, TIMP1, N4BP2L2, TAGLN, ZBTB1, NFYA, FLG, SGPP2, CCDC39, and GTF2IRD2B (Fig. 3A and B) . It is worth mentioning that within the 396 NRF2 down-regulated genes, there was an enrichment of genes that function in transporter activities, as well as in regulation of cell death (Fig. 3C) . Additionally, other well known NRF2
downstream genes were listed in the heatmap from the single pair of stable cell lines (Fig. S1 ).
| ABCF2 has an ARE in its promoter region
One of the putative NRF2 target genes identified in the microarray analysis was ABCF2, a member of the ABC transporter family, whose expression is elevated in clear cell ovarian cancer tissues. gene (−1292 bp to +1069 bp) was cloned (Fig. 4A) . The ABCF2-luciferase and TK-Renilla-luciferase plasmids were cotranfected along with either an NRF2 plasmid or an empty control vector into HEK293T 
| ABCF2 is directly regulated by NRF2
To further verify that NRF2 controls endogenous ABCF2 expression, the effect of both stable and transient NRF2 modulation on ABCF2 mRNA and protein levels was measured. As shown in Fig. 5A , the mRNA level of ABCF2 was 1.2-fold higher in A2780-NRF2 compared to A2780 vector control cell line, and 0.6-fold lower in A2780cp-NRF2-shRNA compared to A2780cp vector control cell line. The protein level of ABCF2 was also higher in A2780-NRF2 and lower in A2780cp-NRF2-shRNA compared to their vector control cell line.
The protein level of ABCF2 in A2780cp was 12.1-fold higher than in A2780 cells (Fig. 5B ). Silencing KEAP1 with siRNA in A2780
increased the protein levels of NRF2, as expected (Fig. 5C ). Moreover, this also caused an increase in ABCF2 protein levels. Consistently, silencing NRF2 with siRNA in A2780cp decreased ABCF2 protein levels. Taken together, these results indicate that ABCF2 expression is controlled by NRF2 (Fig. 5D ).
3.6 | ABCF2 plays a key role in cisplatin resistance in ovarian cancer cells
To determine if ABCF2 is a critical downstream mediator of NRF2-dependent cisplatin resistance in ovarian cancer cells, cell viability assays were performed. In A2780 cells, stable overexpression NRF2 decreases sensitivity to cisplatin (Fig. 5E, left) . However, ABCF2
knockdown with siRNA slightly increased cisplatin sensitivity of A2780-NRF2 cells (Fig. 5E, left) . Conversely, knockdown of NRF2 with siRNA in A2780cp cells increases cisplatin sensitivity, whereas ABCF2
overexpression in A2780cp-NRF2-shRNA cells restores cisplatin | 1549 resistance (Fig. 5E, right) . Further, the parental A2780 cells were transiently transfected with HA-tagged ABCF2. Overexpression of ABCF2 in A2780, as verified by immunoblot analysis, decreased sensitivity to cisplatin compared to cells transfected with an empty control vector (Fig. 6A, 48 h EC 50 : 6.50 ± 0.09 µg/mL and 6.23 ± 0.14 µg/mL, respectively). Conversely, siRNA knockdown of ABCF2 in the cisplatin-resistant A2780cp cells reduced ABCF2
protein levels and increased cisplatin toxicity (Fig. 6B , 48 h EC 50 :
23.63 ± 2.98 µg/mL and 30.75 ± 2.30 µg/mL, respectively). Next, we determined the percentage of apoptotic cells in response to cisplatin treatment using Annexin V/PI staining and flow cytometry. ABCF2
overexpression in itself has no effect on apoptosis, but reduced (E) Cell viability assay. A2780, A2780-NRF2, and A2780-NRF2 cells transfected with ABCF2 siRNA for 48 h, A2780cp, A2780cp-NRF2-shRNA, and A2780cp-NRF2-shRNA transfected with HA-ABCF2 for 24 h were treated with doses of cisplatin for 48 h to determine cell viability. Data are represented as mean ± SD, from two independent experiments, n = 3. *P < 0.05. **P < 0.01 8.15 ± 0.07%, P < 0.01, Fig. 6C ). ABCF2 knockdown using siRNA in A2780cp cells had no effect on apoptosis, but resulted in a higher percentage of apoptotic cells in A2780cp cells treated with cisplatin (44.15 ± 5.53% vs. 23.26 ± 3.78%, P < 0.01, Fig. 6D ).
Finally, we analyzed the expression of ABCF2 in patient samples.
Immunohistochemical staining showed that the HGSOC tissues had significantly higher levels of ABCF2 compared to their NOT controls (Fig. 6E) . The IHC score of the cancer tissues is also higher than that of the normal tissues (P < 0.01, Fig. 6F ).
Taken together, these results suggest that the expression of ABCF2 correlates with cisplatin resistance in ovarian cancer.
| DISCUSSION
Cisplatin resistance is a major obstacle for successful treatment of ovarian cancer. 1,3 NRF2 has been reported to contribute to chemoresistance in a variety of different cancer cell types. [4] [5] [6] While our previous studies have indicated the involvement of NRF2 in cisplatin resistance in ovarian cancer cells, the major NRF2 target genes contributing to the NRF2-dependent cisplatin resistance in ovarian cancer are still not fully characterized. 7 HGSOC is one of the most malignant types of ovarian cancer, and has been associated with a high potential to develop chemoresistance. 27, 28 Immunohistochemical staining of patient-derived samples revealed much higher levels of NRF2 in HGSOC tissues compared to normal tissue controls, indicating a potential correlation of NRF2 levels with chemoresistance in ovarian cancer tissue ( Fig. 1A and B) . Next, we analyzed NRF2 expression levels in ovarian cancer A2780 cells and confirmed that cisplatin-resistant A2780cp have higher NRF2 than parental A2780 (Fig. 1C) . To further understand how NRF2 regulates cisplatin chemoresistance in ovarian cancer cells, we stably overex- Fig. 2C and D) . These data confirm that NRF2 contributes to cisplatin resistance in ovarian cancer.
As a transcription factor, NRF2 exerts its biological effects, including chemoresistance, through direct activation of its target genes that contain an ARE, or indirect activation through upregulation of its downstream genes. 29, 30 For example, NRF2-dependent activation of heme oxygenase 1 (HO-1) is associated with cisplatin resistance in A549 lung cancer cells. 31, 32 Furthermore, the NRF2-dependent activation of a number of ATP binding cassette transporters, such as ABCB6, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, and ABCG2, have also been linked to chemoresistance. 10 To determine other NRF2
target genes that enhance chemoresistance, microarray analysis of two pairs of cell lines with different amounts of NRF2 expression was carried out, and 18 putative NRF2-regulated genes were identified (Fig. 3) . Among these genes, we chose ABCF2 for further characterization since it has been reported to correlate with chemoresistance in clear cell ovarian cancer, [21] [22] [23] and identified a functional ARE in the promoter region of ABCF2, which defines it as a novel NRF2 target gene (Figs. 4 and 5 ).
ABCF2 possesses NBDs, but has no TMD, which makes it different from other members of the ATP binding cassette family since it cannot function as a membrane transporter. 18, 19, 24 Previous studies have
shown that ABCF2 expression correlates with cisplatin resistance in human bladder cancer T24 cell lines 24 and clear cell ovarian cancer.
22
ABCF2 was also indicated to be a potential marker for clear cell adenocarcinomas of the ovary and the uterine corpus. 23, 33 However, the precise molecular mechanism by which ABCF2 mediates cisplatin resistance is not clear. Our study provides evidence for a direct role of ABCF2 in mediating cisplatin resistance, since ABCF2 overexpression rendered A2780 cells more resistant to cisplatin and ABCF2 knockdown rendered resistant A2780 cells more sensitive to cisplatin ( Figure 6 ).
In conclusion, we have identified ABCF2 as a novel NRF2 target gene. We have also provided proof-of-concept in vitro evidence that targeting ABCF2 may be a promising approach to improve the efficacy of cisplatin in treating ovarian cancer. As such, future studies should focus on identifying the molecular mechanisms by which ABCF2
affects the cisplatin response. 
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